Improved overall survival after contralateral risk-reducing mastectomy in brca1/2 mutation carriers with a history of unilateral breast cancer: A prospective analysis

International Journal of Cancer

Volumn 136, Issue 3, 2015, Pages 668-677

  Heemskerk Gerritsen, Bernadette A M ^a   Rookus, Matti A ^b   Aalfs, Cora M ^c,e   Ausems, Margreet G E M ^b,d   Collée, Johanna M ^e   Jansen, Liesbeth ^f   Kets, C Marleen ^g   Keymeulen, Kristien B M I ^h   Koppert, Linetta B ^a   Meijers Heijboer, Hanne E J ^g,i   Mooij, Thea M ^b   Tollenaar, Rob A E M ^j   Vasen, Hans F A ^k   Hogervorst, F B L ^b   Van Leeuwen, F E ^b   Verhoef, S ^b   Schmidt, M K ^b   De Lange, J L ^b   Van Den Ouweland, A M W ^e   Van Deurzen, C H M ^e   Obdeijn, I M ^e   Van Asperen, C J ^j   Wijnen, J T ^j   Devilee, P ^j   Van Cronenburg, T C T E F ^j   Kets, C M ^g   Mensenkamp, A R ^g   Van Der Luijt, R B ^d   Van Os, T A M ^c   Gille, J J P ⁱ   Waisfisz, Q ⁱ   Gomez Garcia E B ^h   Blok, M J ^h   Oosterwijk, J C ^f   Van Der Hout, A H ^f   Mourits, M J ^f   De Bock, G H ^f   Siesling, S ^l   Overbeek, L ^m   Hooning, Maartje J ^a,e   Seynaeve, Caroline ^a,e   more..

^a ERASMUS MC CANCER INSTITUTE   (Netherlands)

^b NETHERLANDS CANCER INSTITUTE   (Netherlands)

^c ACADEMIC MEDICAL CENTER   (Netherlands)

^d UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^e ERASMUS MEDICAL CENTER   (Netherlands)

^f UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

^g RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^h MAASTRICHT UNIVERSITY MEDICAL CENTER   (Netherlands)

ⁱ VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^j LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^k Netherlands Foundation for Detection of Hereditary Tumours   (Netherlands)

^l Netherlands Cancer Registry   (Netherlands)

^m Dutch Pathology Database   (Netherlands)

more..

Author keywords

BRCA1 2; Breast cancer; Contralateral risk reducing mastectomy; Prevention; Survival

Indexed keywords

BREAST CANCER; CANCER MORTALITY; CANCER SURVIVAL; CLINICAL EFFECTIVENESS; CONTROLLED STUDY; DISEASE ASSOCIATION; FEMALE; FOLLOW UP; GENE IDENTIFICATION; GENE MUTATION; HUMAN; MAJOR CLINICAL STUDY; MASTECTOMY; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PROSPECTIVE STUDY; REVIEW; RISK ASSESSMENT; RISK FACTOR; RISK REDUCTION; SURGICAL RISK; SURVIVAL RATE; SURVIVAL TIME; TUMOR SUPPRESSOR GENE; ADULT; AGED; BREAST NEOPLASMS; CLINICAL TRIAL; GENETICS; MIDDLE AGED; MORTALITY; MULTICENTER STUDY; MUTATION; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; BREAST NEOPLASMS; FEMALE; GENES, BRCA1; GENES, BRCA2; HUMANS; MASTECTOMY; MIDDLE AGED; MUTATION; PROSPECTIVE STUDIES;

EID: 84911006155     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.29032     Document Type: Review

References (35)

1. Ford D, Easton DF, Bishop DT, et al. Risks of cancer in BRCA1-mutation carriers. Breast Cancer Linkage Consortium. Lancet 1994;343:692-95.
2. Verhoog LC, Brekelmans CT, Seynaeve C, et al. Survival and tumour characteristics of breastcancer patients with germline mutations of BRCA1. Lancet 1998;351:316-21.
3. Verhoog LC, Brekelmans CTM, Seynaeve C, et al. Survival in hereditary breast cancer associated with germline mutations of BRCA2. J Clin Oncol 1999;17:3396-402.
4. van der Kolk DM, de Bock GH, Leegte BK, et al. Penetrance of breast cancer, ovarian cancer and contralateral breast cancer in BRCA1 and BRCA2 families: high cancer incidence at older age. Breast Cancer Res Treat 2010;124:643-51.
5. Mavaddat N, Peock S, Frost D, et al. Cancer risks for BRCA1 and BRCA2 mutation carriers: results from prospective analysis of EMBRACE. J Natl Cancer Inst 2013;105:812-22.
6. Gao X, Fisher SG, Emami B. Risk of second primary cancer in the contralateral breast in women treated for early-stage breast cancer: a population-based study. Int J Radiat Oncol 2003; 56:1038-45.
7. Bernstein JL, Lapinski RH, Thakore SS, et al. The descriptive epidemiology of second primary breast cancer. Epidemiology 2003;14:552-8.
8. Quan G, Pommier SJ, Pommier RF. Incidence and outcomes of contralateral breast cancers. Am J Surg 2008;195:645-50.
9. Vichapat V, Garmo H, Holmqvist M, et al. Tumor stage affects risk and prognosis of contralateral breast cancer: results from a large Swedish-population-based study. J Clin Oncol 2012;30:3478-85.
10. Schaapveld M, Visser O, Louwman WJ, et al. The impact of adjuvant therapy on contralateral breast cancer risk and the prognostic significance of contralateral breast cancer: a population based study in the Netherlands. Breast Cancer Res Treat 2008;110:189-97.
11. Peralta EA, Ellenhorn JDI, Wagman LD, et al. Contralateral prophylactic mastectomy improves the outcome of selected patients undergoing mastectomy for breast cancer. Am J Surg 2000;180: 439-45.
12. McDonnell SK, Schaid DJ, Myers JL, et al. Efficacy of contralateral prophylactic mastectomy in women with a personal and family history of breast cancer. J Clin Oncol 2001;19:3938-43.
13. van Sprundel TC, Schmidt MK, Rookus MA, et al. Risk reduction of contralateral breast cancer and survival after contralateral prophylactic mastectomy in BRCA1 or BRCA2 mutation carriers. Br J Cancer 2005;93:287-92.
14. Herrinton LJ, Barlow WE, Yu OC, et al. Efficacy of prophylactic mastectomy in women with unilateral breast cancer: a cancer research network project. J Clin Oncol 2005;23:4275-86.
15. Yi M, Meric-Bernstam F, Middleton LP, et al. Predictors of contralateral breast cancer in patients with unilateral breast cancer undergoing contralateral prophylactic mastectomy. Cancer 2009;115:962-71.
16. Kiely B, Jenkins M, McKinley J, et al. Contralateral risk-reducing mastectomy in BRCA1 and BRCA2 mutation carriers and other high-risk women in the Kathleen Cuningham Foundation Consortium for Research into Familial Breast Cancer (kConFab). Breast Cancer Res Treat 2010; 120:725-26.
17. Boughey J, Hoskin T, Degnim A, et al. Contralateral prophylactic mastectomy is associated with a survival advantage in high-risk women with a personal history of breast cancer. Ann Surg Oncol 2010;17:2702-09.
18. Chung A, Huynh K, Lawrence C, et al. Comparison of patient characteristics and outcomes of contralateral prophylactic mastectomy and unilateral total mastectomy in breast cancer patients. Ann Surg Oncol 2012;19:2600-06.
19. Evans DGR, Ingham SL, Baildam A, et al. Contralateral mastectomy improves survival in women with BRCA1/2-associated breast cancer. Breast Cancer Res Treat 2013;140:135-42.
20. Bedrosian I, Hu C-Y, Chang GJ. Populationbased study of contralateral prophylactic mastectomy and survival outcomes of breast cancer patients. J Natl Cancer Inst 2010;102:401-09.
21. Metcalfe K, Gershman S, Ghadirian P, et al. Contralateral mastectomy and survival after breast cancer in carriers of BRCA1 and BRCA2 mutations: retrospective analysis. BMJ 2014;348: g226.
22. Pijpe A, Manders P, Brohet RM, et al. Physical activity and the risk of breast cancer in BRCA1/2 mutation carriers. Breast Cancer Res Treat 2010; 120:235-44.
23. Klaren HM, van't Veer LJ, van Leeuwen FE, et al. Potential for bias in studies on efficacy of prophylactic surgery for BRCA1 and BRCA2 mutation. J Natl Cancer Inst 2003;95:941-47.
24. Simon R, Makuch R. A non-parametric graphical representation of the relationship between survival and the occurrence of an event: application to responder versus non-responder bias. Stat Med 1984;3:35-44.
25. Schultz LR, Peterson EL, Breslau N. Graphing survival curve estimates for time-dependent covariates. Int J Meth Psych Res 2002;11:68-74.
26. Heemskerk-Gerritsen BAM, Hooning MJ, Jager A, et al. Is risk-reducing mastectomy in BRCA1/2 mutation carriers with a history of unilateral breast cancer beneficial with respect to distant disease free survival and overall survival? Eur J Cancer 2010 (suppl);8:206-06.
27. Narod SA. The impact of contralateral mastectomy on mortality in BRCA1 and BRCA2 mutation carriers with breast cancer. Breast Cancer Res Treat 2011;128:581-83.
28. Graeser MK, Engel C, Rhiem K, et al. Contralateral breast cancer risk in BRCA1 and BRCA2 mutation carriers. J Clin Oncol 2009;27: 5887-92.
29. Bouchardy C, Benhamou S, Fioretta G, et al. Risk of second breast cancer according to estrogen receptor status and family history. Breast Cancer Res Treat 2010:1-9.
30. Reding KW, Bernstein JL, Langholz BM, et al. Adjuvant systemic therapy for breast cancer in BRCA1/BRCA2 mutation carriers in a population-based study of risk of contralateral breast cancer. Breast Cancer Res Treat 2010;123: 491-98.
31. Pierce LJ, Phillips KA, Griffith KA, et al. Local therapy in BRCA1 and BRCA2 mutation carriers with operable breast cancer: comparison of breast conservation and mastectomy. Breast Cancer Res Treat 2010;121:389-98.
32. Veronesi U, Cascinelli N, Mariani L, et al. Twenty-year follow-up of a randomized study comparing breast-conserving surgery with radical mastectomy for early breast cancer. New Engl J Med 2002;347:1227-32.
33. Meijers-Heijboer H, Brekelmans CT, Menke-Pluymers M, et al. Use of genetic testing and prophylactic mastectomy and oophorectomy in women with breast or ovarian cancer from families with a BRCA1 or BRCA2 mutation. J Clin Oncol 2003;21:1675-81.
34. Beattie M, Crawford B, Lin F, et al. Uptake, time course, and predictors of risk-reducing surgeries in BRCA carriers. Genet Test Mol Biomarkers 2009;13:51-56.
35. Domchek SM, Friebel TM, Singer CF, et al. Association of risk-reducing surgery in BRCA1 or BRCA2 mutation carriers with cancer risk and mortality. J Am Med Assoc 2010;304:967-75.